Phloroglucinol
drug drugOn this page
Also known as Dilospan sNSC-1572PhloroglucinSpasfonSpasfon-lyocSym-trihydroxybenzeneSID29218028
Summary
Phloroglucinol (CHEMBL473159) is a phase-3 clinical-stage small molecule (ATC A03AX12) targeting TRPC6; indicated across 1 condition.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: A03AX12
- Targets: 1 (TRPC6)
- Indications: 1 condition
- Clinical trials: 4
- Chemistry: 126.11 Da · C6H6O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL473159 |
| Name | Phloroglucinol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 359 |
| ChEBI | CHEBI:16204 |
| ATC | A03AX12 |
| Molecular formula | C6H6O3 |
| Molecular weight | 126.11 |
| InChIKey | QCDYQQDYXPDABM-UHFFFAOYSA-N |
SMILES: C1=C(C=C(C=C1O)O)O
IUPAC name: benzene-1,3,5-triol
ChEBI definition: A benzenetriol with hydroxy groups at position 1, 3 and 5.
Other ChEBI roles (chemical / environmental): algal metabolite.
Also known as: Dilospan s, NSC-1572, Phloroglucin, Phloroglucinol, Spasfon, Spasfon-lyoc, Sym-trihydroxybenzene, phloroglucinol, SID29218028, PHLOROGLUCINOL, PHLOROGLUCIN, phloroglucin
Patent coverage: 14,353 distinct patent families (35,205 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| TRPC6 | TRPC6 | 0.2% | Q9Y210 |
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-secretase 1.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): TRPC6.
Top Reactome pathways
4 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Effects of PIP2 hydrolysis | 1 | TRPC6 |
| Elevation of cytosolic Ca2+ levels | 1 | TRPC6 |
| TRP channels | 1 | TRPC6 |
| Role of second messengers in netrin-1 signaling | 1 | TRPC6 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| monoatomic cation transport | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| single fertilization | 1 |
| neuron differentiation | 1 |
| positive regulation of ion transmembrane transporter activity | 1 |
| positive regulation of neuron differentiation | 1 |
| negative regulation of dendrite morphogenesis | 1 |
| regulation of cytosolic calcium ion concentration | 1 |
| positive regulation of calcium ion transport | 1 |
| cellular response to hydrogen peroxide | 1 |
| calcium ion transmembrane transport | 1 |
| cellular response to hypoxia | 1 |
| monoatomic ion transport | 1 |
| calcium ion transport | 1 |
| monoatomic ion transmembrane transport | 1 |
Indications & clinical
Indications
1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01842932 | PHASE4 | UNKNOWN | Usefulness Of Flospan As A Premedication For Colonoscopy |
| NCT01061073 | PHASE3 | COMPLETED | Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial |
| NCT06233643 | Not specified | UNKNOWN | The Efficiency of Acupuncture Combined Intradermal Sterile Water Application in Acute Renal Colic |
| NCT07184099 | Not specified | COMPLETED | Phloroglucinol Effectiveness on Shortening the Duration of Active Phase of Labor |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CLEMIZOLE | ChEMBL | Phase 2 | TRPC6 |
Related Atlas pages
- Genes: TRPC6